Regeneron reported Tuesday that its antibody cocktail for coronavirus has show a reduction in overall infections seen within the first week, with 100% prevention of symptomatic infections. CNBC’s Meg Tirrell reports. For access to live and exclusive video from CNBC…
A number of start-ups and major tech companies like Microsoft, Ticketmaster, Apple, and Google are interested in vaccine or immunization passports to help reopen the economy. But public health officials are weary, warning the apps are pointless without more knowledge…
The U.S. began vaccinating the population against the coronavirus earlier this month, but mass adoption is not a guarantee. Roughly four in ten Americans say they would “definitely” or “probably” not get a vaccine, according to a recent survey by…
CNBC’s “Closing Bell” team reports on President-elect Joe Biden receiving his first dose of Pfizer’s coronavirus vaccine. For access to live and exclusive video from CNBC subscribe to CNBC PRO: President-elect Joe Biden received a Covid-19 vaccine on live television…
Ronny Gal, Bernstein senior analyst, joins ‘Closing Bell’ to discuss the timeline for when the U.S. could reach herd immunity on Covid-19 once there is a readily available vaccine. He also talks about the vaccine’s impact on markets. For access…
Pharmaceutical giant Merck said it plans to acquire privately-held OncoImmune for $425 million in cash, gaining rights to an under-the-radar drug that’s shown striking results in hospitalized patients with Covid-19. Dr. Yang Liu, founder, CEO and chief scientific officer of…
